The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
|Videos|May 17, 2011
Jane Armer on Findings From Her Lymphedema Research
Author(s)Jane M. Armer, RN, PhD
Jane Armer the director of ALFP on Findings From Her Lymphedema Research
Advertisement
American Lymphedema Framework Project (ALFP) Director Jane M. Armer, RN, PhD, School of Nursing, University of Missouri, Columbia, describes the results from her research showing that 90% of therapists treat patients using the "golden standard" of lymphedema care and that the majority of the time treatment is to the upper extremities in hospital outpatient settings.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5